Life Science Investing Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Life Science Investing Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Life Science Investing Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000
Life Science Investing Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
Providence Gold Mines Inc. Receives Regulatory Approvals for Fundamental Transaction & The La Dama de Oro Gold Property NI 43-101 Report
